JP2022545553A - Ａ型インフルエンザ感染の治療のための組成物及び方法 - Google Patents

Ａ型インフルエンザ感染の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2022545553A
JP2022545553A JP2022513477A JP2022513477A JP2022545553A JP 2022545553 A JP2022545553 A JP 2022545553A JP 2022513477 A JP2022513477 A JP 2022513477A JP 2022513477 A JP2022513477 A JP 2022513477A JP 2022545553 A JP2022545553 A JP 2022545553A
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
fluab
days
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513477A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021041989A5 (https=
JP2022545553A5 (https=
Inventor
フィリップ・エス・パン
リン・イー・コノリー
エリック・モガリアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vir Biotechnology Inc
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of JP2022545553A publication Critical patent/JP2022545553A/ja
Publication of JPWO2021041989A5 publication Critical patent/JPWO2021041989A5/ja
Publication of JP2022545553A5 publication Critical patent/JP2022545553A5/ja
Priority to JP2025084157A priority Critical patent/JP2025124708A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022513477A 2019-08-29 2020-08-28 Ａ型インフルエンザ感染の治療のための組成物及び方法 Pending JP2022545553A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025084157A JP2025124708A (ja) 2019-08-29 2025-05-20 Ａ型インフルエンザ感染の治療のための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962893747P 2019-08-29 2019-08-29
US62/893,747 2019-08-29
US202062993519P 2020-03-23 2020-03-23
US62/993,519 2020-03-23
US202063040966P 2020-06-18 2020-06-18
US63/040,966 2020-06-18
PCT/US2020/048635 WO2021041989A1 (en) 2019-08-29 2020-08-28 Compositions and methods for treatment of influenza a infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025084157A Division JP2025124708A (ja) 2019-08-29 2025-05-20 Ａ型インフルエンザ感染の治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022545553A true JP2022545553A (ja) 2022-10-27
JPWO2021041989A5 JPWO2021041989A5 (https=) 2023-09-04
JP2022545553A5 JP2022545553A5 (https=) 2023-09-04

Family

ID=72473986

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513477A Pending JP2022545553A (ja) 2019-08-29 2020-08-28 Ａ型インフルエンザ感染の治療のための組成物及び方法
JP2025084157A Pending JP2025124708A (ja) 2019-08-29 2025-05-20 Ａ型インフルエンザ感染の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025084157A Pending JP2025124708A (ja) 2019-08-29 2025-05-20 Ａ型インフルエンザ感染の治療のための組成物及び方法

Country Status (11)

Country Link
US (1) US20220306728A1 (https=)
EP (1) EP4021502A1 (https=)
JP (2) JP2022545553A (https=)
KR (1) KR20220061999A (https=)
CN (1) CN115052630A (https=)
AU (1) AU2020335922A1 (https=)
BR (1) BR112022003529A2 (https=)
CA (1) CA3148990A1 (https=)
IL (1) IL290752B2 (https=)
MX (1) MX2022002447A (https=)
WO (1) WO2021041989A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507963A (ja) * 2007-12-26 2011-03-10 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体
JP2016138097A (ja) * 2015-01-28 2016-08-04 ファイザー・インク 安定な水性抗体製剤
WO2019222674A1 (en) * 2018-05-18 2019-11-21 Chan Zuckerberg Biohub, Inc. Epitope restriction for antibody selection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2017123685A1 (en) * 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507963A (ja) * 2007-12-26 2011-03-10 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体
JP2016138097A (ja) * 2015-01-28 2016-08-04 ファイザー・インク 安定な水性抗体製剤
WO2019222674A1 (en) * 2018-05-18 2019-11-21 Chan Zuckerberg Biohub, Inc. Epitope restriction for antibody selection

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ＣＥＬＬ, vol. １６６, JPN6024031124, 28 July 2016 (2016-07-28), pages 596 - 608, ISSN: 0005386397 *
MAEDA A. ET AL., MABS, vol. 9:5, JPN6025001591, 2017, pages 844 - 853, ISSN: 0005507086 *
STUBENRAUCH KAY ET AL., JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. Volume 52, Issue 2, JPN6025001595, 2010, pages 249 - 254, ISSN: 0005507089 *
ＴＨＥ ＪＯＵＲＮＡＬ ＯＦ ＩＮＦＥＣＴＩＯＵＳ ＤＩＳＥＡＳＥＳ, vol. ２１６, JPN6024031123, 17 June 2017 (2017-06-17), pages 356 - 365, ISSN: 0005507085 *
新見 伸吾: "『１．非臨床におけるバイオ医薬品の免疫原性評価』", 谷本学校 毒性質問箱, vol. 2017巻第19号, JPN6025001596, 2017, pages 88 - 98, ISSN: 0005507088 *
石井 明子 他, 日薬理誌（FOLIA PHARMACOL. JPN.）, vol. 136, JPN6025001594, 2010, pages 280 - 284, ISSN: 0005507087 *

Also Published As

Publication number Publication date
CN115052630A (zh) 2022-09-13
WO2021041989A9 (en) 2021-05-14
BR112022003529A2 (pt) 2022-05-24
KR20220061999A (ko) 2022-05-13
IL290752B1 (en) 2025-10-01
IL290752B2 (en) 2026-02-01
EP4021502A1 (en) 2022-07-06
AU2020335922A1 (en) 2022-03-24
US20220306728A1 (en) 2022-09-29
WO2021041989A1 (en) 2021-03-04
CA3148990A1 (en) 2021-03-04
MX2022002447A (es) 2022-08-08
JP2025124708A (ja) 2025-08-26
IL290752A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
JP7719725B2 (ja) Ａ型インフルエンザ感染の抗体及び治療法
EP2846832B1 (en) Novel ha binding agents
US11230593B2 (en) Compositions and methods for treating and preventing influenza
US20230257449A1 (en) Compositions and methods for treating and preventing influenza
JP2022545553A (ja) Ａ型インフルエンザ感染の治療のための組成物及び方法
JP2023553888A (ja) Ａ型インフルエンザ感染の治療のための抗体及び方法
EA050175B1 (ru) Композиции и способы лечения инфекции, вызываемой вирусом гриппа а
HK40074693A (en) Compositions and methods for treatment of influenza a infection
HK40067817A (en) Antibodies and methods for treatment of influenza a infection
EA048000B1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
HK40035221A (en) Novel ha binding agents

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230825

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250121